this from the Wilson report is a sad commentary really.
"GSK is still ignoring the retail channel for Relenza. The most recent IMS Health data reports ~10-15 thousand US Relenza prescriptions, monthly."
If so why? perhaps cause they dont have capacity yet
- Forums
- ASX - By Stock
- BTA
- strange???